BCL2 and neoplasm: Consistent with the results in Fig. 6i, e-375i treatment resulted in reduced expression of p-STAT3 and BCL2, increased cleaved-PARP1, and significantly decreased Ki67 in tumor tissue (Fig. 7i, j).